Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
A proactive clinical practice is to refer all newly diagnosed myelofibrosis patients for a transplant consultation, irrespective of their initial risk score. This preemptive step helps overcome significant logistical delays in finding a suitable donor, which is particularly crucial for patients from diverse ethnic backgrounds where donor availability is limited.
Related Insights
The sequence of therapies like bispecifics and CAR-T critically impacts future options and outcomes. This necessitates early, strategic collaboration between community oncologists and academic centers to plan a patient's entire treatment journey, not just the next immediate step.
While newer, less toxic therapies like HMA-Venetoclax empower community oncologists to treat AML, this creates a new risk: failing to refer younger, curable patients to tertiary centers for allogeneic transplant, which remains the only curative option for many adverse-risk patients.
A diagnosis of myelofibrosis without a JAK2, CALR, or MPL mutation should be treated as a red flag, not a final diagnosis. It warrants a deeper investigation for alternative causes, such as MDS/MPN overlap syndromes or secondary fibrosis from other conditions like autoimmune disease or hairy cell leukemia.
The clinical decision for newly diagnosed, transplant-ineligible myeloma patients has fundamentally shifted. Instead of determining who is eligible for a quadruplet regimen, the primary question for clinicians is now identifying the few patients who are not fit enough for this new standard of care.
A critical challenge in myelofibrosis care is that the optimal time for a curative transplant is when patients feel well, often due to effective JAK inhibitor therapy. This feeling of well-being makes them reluctant to undergo the high-risk procedure. Waiting until they feel sick makes the transplant less likely to succeed.
A patient's risk score primarily determines their candidacy for a stem cell transplant. However, the decision to start a JAK inhibitor is driven by symptoms like splenomegaly and constitutional issues, regardless of the patient's formal risk status. This decouples two key treatment decisions.
For older, transplant-ineligible myeloma patients, quadruplet regimens are not administered at full strength. Clinicians proactively reduce doses of bortezomib, lenalidomide, and dexamethasone based on patient fitness and renal function to manage toxicity while maintaining efficacy.
Based on findings from the DETERMINATION-1 and MIDAS trials, which questioned the overall survival benefit of early transplant, new strategies are emerging. The DETERMINATION-2 trial will use iberdomide-based therapy and defer transplant for standard-risk, MRD-negative patients, reserving it for higher-risk cases.
Experts vehemently state that patients ineligible for autologous stem cell transplant are not necessarily ineligible for CAR-T therapy. This corrects a critical misconception, urging community oncologists to refer these patients for CAR-T evaluation as they may still be candidates.
The DETERMINATION trial found that African American patients, who are often Duffy null, had better outcomes with RVD alone versus early transplant. The Duffy null phenotype reduces the ability to absorb inflammatory stress, suggesting that pro-inflammatory treatments like high-dose chemotherapy and transplant may be less advantageous for this population.
